top of page

Expanding the Conversation Around GLP-1 Medications


It’s time to broaden the conversation about GLP-1 medications like Semaglutide/Tirzepatide. While these treatments are gaining popularity for their role in weight loss and metabolic health, I caution against long-term use of high doses or relying on any single "miracle drug" for lasting health improvements.


However, it’s not always about the tool itself but rather how, why, and when it’s used. In certain situations, Semaglutide/Tirzepatide, when thoughtfully applied as part of a broader healing protocol, can play a positive role. Particularly, microdosing these medications may offer surprising benefits for metabolic health and beyond.


In this post, we’ll explore the potential benefits of Semaglutide/Tirzepatide, the strategic use of microdosing, how to naturally support your body’s GLP-1 production, and the risks you should be aware of.


What Are Semaglutide and Tirzepatide? An Overview of GLP-1 and Peptide Therapy

Semaglutide (sold under brand names Ozempic and Wegovy) and Tirzepatide (sold as Mounjaro and Zepbound) were originally developed to help manage blood sugar in type 2 diabetes. Both have gained widespread attention for their effects on appetite regulation, blood sugar control, and weight loss.


As peptides—short chains of amino acids—these medications work by mimicking the body’s natural GLP-1 hormone, which is released when we eat. Tirzepatide goes a step further by also acting on GIP (glucose-dependent insulinotropic polypeptide) receptors, potentially enhancing its metabolic benefits.


When these medications bind to GLP-1 and GIP receptors, they trigger several responses:

  • Signal your brain that you’re full

  • Stimulate insulin release from your pancreas

  • Slow gastric emptying, keeping you full longer


It’s easy to see why Semaglutide/Tirzepatide have been labeled "wonder drugs" for weight loss. However, using them long-term at high doses can come with a host of side effects, from muscle loss to gastrointestinal issues and even pancreatitis. More importantly, using these medications in isolation doesn’t address the root cause of weight gain or metabolic dysfunction.


Taking a Different Approach: Microdosing Semaglutide/Tirzepatide

While I’ve expressed concerns about how GLP-1 medications are commonly marketed as a one-size-fits-all solution for weight loss, the medications themselves aren’t the issue. Rather, it’s how we approach their use.

Microdosing—using lower doses strategically—can be a powerful tool when combined with efforts to heal your body’s metabolic processes. By taking a holistic approach that addresses the underlying causes of metabolic dysfunction, you can use Semaglutide/Tirzepatide temporarily to kick start healing while working to restore your body’s natural GLP-1 production.


Does Microdosing Semaglutide/Tirzepatide Work?

The simple answer: yes, but it’s important to recognize that microdosing is part of a bigger picture. When used thoughtfully, microdosing can support metabolic function without the need for high doses or long-term dependency. It’s about combining this therapy with lifestyle interventions that target metabolic health, such as diet, exercise, and other holistic approaches.


Who Should Consider Microdosing?

Microdosing Semaglutide/Tirzepatide isn’t for everyone. It’s not the first step for weight loss or metabolic health but may be beneficial for those who have tried other interventions without success. It’s particularly helpful for people who are motivated to do the deeper work of healing and not just seeking a quick fix.


Potential Benefits of Semaglutide/Tirzepatide

While research has primarily focused on higher doses, Semaglutide/Tirzepatide have shown promise in several areas, including:

  • Appetite control and weight loss – These medications help regulate appetite and gastric emptying, which can support weight loss.

  • Blood sugar control – Initially developed for diabetes, both have been proven to improve blood sugar levels and insulin sensitivity.

  • Cardiovascular health – Studies show these drugs reduce the risk of heart disease and related events, especially in individuals with obesity.

  • Neuroprotection – Research suggests GLP-1 receptor agonists may lower the risk of Alzheimer’s, likely due to their positive effects on insulin signaling.

  • Inflammation reduction – By improving metabolism and insulin sensitivity, these medications can help lower inflammation in the body.


Risks and Side Effects of Semaglutide/Tirzepatide

While the risks are lower when microdosing, side effects can still occur. Potential risks include:

  • Gastrointestinal symptoms (nausea, vomiting, diarrhea, etc.)

  • Muscle loss

  • Low blood sugar

  • Pancreatitis

  • Gallbladder issues

  • Thyroid tumors


A Simple Guide to Microdosing Semaglutide/Tirzepatide

If you’re considering microdosing, here are some key strategies to follow:

  • Find your lowest effective dose – Start with the smallest dose that produces noticeable changes, such as feeling fuller longer or experiencing fewer cravings.

  • Support natural GLP-1 production – Incorporate GLP-1-boosting foods, exercise, and intermittent fasting into your routine. Supplements like berberine and curcumin can also be helpful.

  • Restore metabolic health – Identify and address the root causes of metabolic dysfunction, such as gut health or hormone imbalances, with the help of a functional medicine practitioner.

  • Support your body throughout the process – Incorporate strength training, gut health support, and adequate protein intake to protect against side effects.


The Bottom Line on Microdosing Semaglutide/Tirzepatide

Microdosing Semaglutide/Tirzepatide can be a valuable part of a comprehensive plan to heal your metabolism, improve metabolic flexibility, and achieve sustained weight loss. However, it’s most effective when used as part of a holistic approach rather than a stand-alone solution.


If you’re interested in exploring whether microdosing Semaglutide/Tirzepatide is right for you, working with a functional medicine practitioner can help ensure you’re taking a thoughtful, personalized approach that supports your long-term health. You can reach out to our clinic for more information 520-222-6208.


SOURCES


  1. Ryan, D. H., Lingvay, I., Deanfield, J., Kahn, S. E., Barros, E., Burguera, B., ... & Kushner, R. F. (2024). Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nature medicine, 1-9.

  2. Berra, C. C., Rossi, M. C., Mirani, M., Ceccarelli Ceccarelli, D., Romano, C., Sassi, L., ... & Fiorina, P. (2023). Real world effectiveness of subcutaneous semaglutide in type 2 diabetes: A retrospective, cohort study (Sema-MiDiab01). Frontiers in Endocrinology, 13, 1099451.

  3. Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., ... & Ryan, D. H. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 389(24), 2221-2232.

  4. Wang, W., Wang, Q., Qi, X., Gurney, M., Perry, G., Volkow, N. D., ... & Xu, R. (2024). Associations of semaglutide with first‐time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real‐world data in the US. Alzheimer's & Dementia, 20(12), 8661-8672.

  5. Lenharo, M. (2024). Obesity drugs have another superpower: taming inflammation. Nature.

  6. Ruder, K. (2023). As semaglutide’s popularity soars, rare but serious adverse effects are emerging. Jama.

  7. Clemmensen, K. K., Quist, J. S., Vistisen, D., Witte, D. R., Jonsson, A., Pedersen, O., ... & Færch, K. (2020). Role of fasting duration and weekday in incretin and glucose regulation. Endocrine Connections, 9(4), 279-288.

 
 
 

Kommentare

Kommentare konnten nicht geladen werden
Es gab ein technisches Problem. Verbinde dich erneut oder aktualisiere die Seite.
bottom of page